Healthon Inc. dba Healthon
4 extracted findings · 1 model-assigned issue type
FDA source excerpt, selected passage
“Same active ingredient as Wegovy and Ozempic.”
Findings and supporting evidence
Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.
Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.
Supporting FDA text
Source excerpt · automated text-match check“Same active ingredient as Wegovy and Ozempic.”
Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.
Supporting FDA text
Source excerpt · automated text-match check“Same active ingredient as Mounjaro pens and Zepbound.”
Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.
Supporting FDA text
Source excerpt · automated text-match check“Clinically proven weight loss”
Website claims falsely imply compounded semaglutide and tirzepatide are the same as FDA-approved products.
Supporting FDA text
Source excerpt · automated text-match check“The active ingredient in our formula is FDA-approved….”
Findings extracted from the letter
Selected FDA passages, not the complete letter.
Source passage selected by the model
Source passage selected by the model
Source passage selected by the model
Source passage selected by the model
What FDA requested
Model-assisted summary. Consult the letter for complete requests and conditions.
- Provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps taken to address any violations
- Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation
- If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration
- If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so